[{"indications": "Indications\u00a0see under Dose; contraception (section 7.3.2.2); malignant\r\ndisease (section\r\n8.3.2)", "name": "MEDROXYPROGESTERONE ACETATE - FEMALE SEX HORMONES", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "6 Endocrine system", "6.4 Sex hormones", "6.4.1 Female sex hormones", "6.4.1.2 Progestogens", "MEDROXYPROGESTERONE ACETATE"], "cautions": "Cautions\u00a0\n(From 6.4.1.2 Progestogens: British National Formulary)\nCautions\u00a0Progestogens should be used with caution in conditions that may worsen with fluid retention e.g. epilepsy, hypertension, migraine, asthma, or cardiac dysfunction, and in those susceptible to thromboembolism (particular caution with high dose). Care is also required in those with a history of depression. Progestogens can decrease glucose tolerance and patients with diabetes should be monitored closely. For interactions see Appendix 1 (progestogens).", "side-effects": "Side-effects\u00a0see notes above; indigestion", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/4349.htm", "doses": ["By mouth, 2.5\u201310\u00a0mg daily for 5\u201310 days\r\nbeginning on day 16 to 21 of cycle, repeated for 2 cycles in dysfunctional\r\nuterine bleeding and 3 cycles in secondary amenorrhoea", "Mild to moderate endometriosis, 10\u00a0mg 3 times daily for 90 consecutive\r\ndays, beginning on day 1 of cycle", "Progestogenic opposition of oestrogen HRT, 10\u00a0mg daily for the\r\nlast 14 days of each 28-day oestrogen HRT cycle"], "pregnancy": "Pregnancy\u00a0section 8.3.2"}, {"indications": "Indications\u00a0see under Dose; contraception (section 7.3.2.2); malignant\r\ndisease (section\r\n8.3.2)", "name": "MEDROXYPROGESTERONE ACETATE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "6 Endocrine system", "6.4 Sex hormones", "6.4.1 Female sex hormones", "6.4.1.2 Progestogens", "MEDROXYPROGESTERONE ACETATE"], "cautions": "Cautions\u00a0\n(From 6.4.1.2 Progestogens: British National Formulary)\nCautions\u00a0Progestogens should be used with caution in conditions that may worsen with fluid retention e.g. epilepsy, hypertension, migraine, asthma, or cardiac dysfunction, and in those susceptible to thromboembolism (particular caution with high dose). Care is also required in those with a history of depression. Progestogens can decrease glucose tolerance and patients with diabetes should be monitored closely. For interactions see Appendix 1 (progestogens).", "side-effects": "Side-effects\u00a0see notes above; indigestion", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/4349.htm", "doses": ["By mouth, 2.5\u201310\u00a0mg daily for 5\u201310 days\r\nbeginning on day 16 to 21 of cycle, repeated for 2 cycles in dysfunctional\r\nuterine bleeding and 3 cycles in secondary amenorrhoea", "Mild to moderate endometriosis, 10\u00a0mg 3 times daily for 90 consecutive\r\ndays, beginning on day 1 of cycle", "Progestogenic opposition of oestrogen HRT, 10\u00a0mg daily for the\r\nlast 14 days of each 28-day oestrogen HRT cycle"], "pregnancy": "Pregnancy\u00a0section 8.3.2"}, {"indications": "Indications\u00a0\n(From 8.3.2 Progestogens: British National Formulary)\n8.3.2 Progestogens; contraception (%s\n(From 7.3.2.2 Parenteral progestogen-only contraceptives: British National Formulary)\n7.3.2.2 Parenteral progestogen-only contraceptives); other\r\nindications (%s\n(From 6.4.1.2 Progestogens: British National Formulary)\n6.4.1.2 Progestogens)", "name": "MEDROXYPROGESTERONE ACETATE - SEX HORMONES AND HORMONE ANTAGONISTS IN MALIGNANT DISEASE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "8 Malignant disease and immunosuppression", "8.3 Sex hormones and hormone antagonists in malignant disease", "8.3.2 Progestogens", "MEDROXYPROGESTERONE ACETATE"], "cautions": "Cautions\u00a0see section\r\n6.4.1.2 and notes above; interactions: Appendix 1 (progestogens)", "side-effects": "Side-effects\u00a0see section\r\n6.4.1.2 and notes above; glucocorticoid effects at high\r\ndose may lead to a cushingoid syndrome", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/4811.htm", "doses": ["See preparations below", " endometrial and renal cell cancer, 200\u2013400\u00a0mg daily;\r\nbreast cancer, 400\u2013800\u00a0mg daily"], "pregnancy": "Pregnancy\u00a0avoid\u2014genital malformations and cardiac defects reported;\r\nsee also Parenteral Progestogen-only Contraceptives (section 7.3.2.2)"}]